RaFIST: A Radiomics-Based Tool for Intratumoral Fibrosis Stratification in Non-Small Cell Lung Cancer
Launched by JINLING HOSPITAL, CHINA · Apr 1, 2025
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Solid pulmonary nodule detected on CECT within 3 weeks pre-resection
- • No history of previous treatment such as chemotherapy, or radiotherapy
- Exclusion Criteria:
- • Unavailable pathological sections
- • Missing CT images or hard-to-annotate CT images
- • Undergone anticancer therapy before CT
- • Loss to follow-up
- • Concurrent other malignant tumors
About Jinling Hospital, China
Jinling Hospital, located in Nanjing, China, is a prominent healthcare institution renowned for its commitment to advanced medical research and comprehensive patient care. As a key clinical trial sponsor, Jinling Hospital leverages its robust clinical expertise and state-of-the-art facilities to facilitate innovative research initiatives that aim to improve therapeutic outcomes across various medical fields. With a dedicated team of experienced researchers and healthcare professionals, the hospital fosters collaboration and adheres to rigorous ethical standards, ensuring the integrity and quality of its clinical trials while contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported